Effect of administering recombinant XXXX to @entity1 with postpartum @entity417 : a meta-analysis.

@entity1 @entity417 @entity5301 @entity1307 @entity68
OBJECTIVES: Recombinant @entity1307 ( @entity5301 ) has been administered to @entity1 with postpartum @entity417 in an attempt to accelerate their increase in hemoglobin concentration and reduce postpartum transfusions. However, it is not clear whether such an approach can be supported by evidence and should be generally recommended. STUDY DESIGN AND METHODS: Medical and scientific literature from January 1990 to December 2002 was searched and studies that reported the administration of @entity5301 to @entity1 with postpartum @entity417 were evaluated. RESULTS: Eight evaluated studies reported an aggregate of 480 @entity1 ; 300 @entity5301 recipients and 180 controls. Significant diversity in design was observed in @entity5301 dose, route of @entity5301 administration, @entity68 supplementation, and baseline hemoglobin. No significant safety concerns were reported. In all five studies where it was reported, 4 to 7 days after beginning treatment, greater increases in hemoglobin concentration were observed among the @entity5301 recipients than among the controls. However, heterogeneity of results (Q-test statistic, p<0.01) indicated that it was not appropriate to apply summary statistics. The effect of @entity5301 on postpartum transfusion rate was not measurable by summary statistics because of the limited number of transfusions given (no transfusions among the 300 @entity5301 recipients vs two transfusions among the 180 controls). CONCLUSION: Administration of @entity5301 to @entity1 with postpartum @entity417 appears to be safe, and is associated with a trend toward a faster increase in hemoglobin concentration. However, its efficacy in terms of diminishing postpartum transfusions is unproven.
